Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: mcs-110, pd-360324 | 0.81 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 15 Parkinson's papers of 3,415 | 0.64 |
| pathways Reactome | 7 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 5070
Sealed predictions
- CSF1 in dopamine neurons, braak-0.58 (p 0.104) → -0.62 (p 0.073)receipt 5077
Swarm cases
receipt 5077: CSF1 in dopamine neurons, braak
- power
- full sample -0.57 (p 0.013, n 18), 95% CI -0.82 to -0.14. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.63 (p 0.0053, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.67 (p 0.0022, n 18). not the mix.
- skeptic
- leave-one-out range -0.72 to -0.52, sign flips 0; without severely affected donors -0.57 (p 0.013, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CSF1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts